Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib in KRAS G12C NSCLC Treatment

Revolution Medicines has received FDA Breakthrough Therapy Designation for elironrasib, a RAS(ON) G12C-selective inhibitor, for treating adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor. The designation is based on encouraging clinical data from the Phase 1 RMC-6291-001 clinical trial.

Revolution Medicines (NASDAQ: RVMD) has received a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting Breakthrough Therapy Designation to its drug elironrasib. This designation is for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor.

The Breakthrough Therapy Designation is based on encouraging clinical data from the Phase 1 RMC-6291-001 clinical trial, which demonstrated highly competitive antitumor activity, differentiated safety profile, and compelling objective response rate and progression-free survival. Elironrasib is a RAS(ON) G12C-selective inhibitor that targets the RAS(ON) form of the RAS G12C variant, present in approximately 12% of NSCLC cases.

The FDA Breakthrough status for elironrasib significantly accelerates the approval pathway, addressing a critical unmet need in KRAS G12C lung cancer. NSCLC accounts for 80%-85% of all lung cancers, with most patients diagnosed at advanced stages. KRAS mutations appear in nearly 30% of NSCLC cases, with G12C being the most common variant. Currently, there are no FDA-approved RAS-targeted inhibitors for KRAS G12C NSCLC, highlighting the substantial unmet need.

The Breakthrough Therapy Designation provides Revolution Medicines with enhanced FDA interaction, potential eligibility for accelerated approval and priority review, and reinforces the company's emerging leadership in the competitive RAS inhibitor landscape. This designation follows the recent Breakthrough Therapy Designation for daraxonrasib, another RAS(ON) inhibitor, for patients with advanced RAS mutant pancreatic cancer, further validating the company's platform approach to targeting RAS-driven cancers.

Revolution Medicines is exploring elironrasib monotherapy and combinations in various treatment settings and continues to prioritize multiple options for advancing its development. The company's R&D pipeline includes other RAS(ON) inhibitors targeting different KRAS mutations, such as daraxonrasib (RMC-6236) and zoldonrasib (RMC-9805).

This designation marks a significant step forward in addressing the critical unmet medical need in KRAS G12C lung cancer. The Breakthrough Therapy Designation is intended to expedite the development and review of potential new medicines designed to treat serious conditions and address significant unmet medical needs. Pursuant to FDA guidelines, the medicine must have shown encouraging preliminary clinical evidence that demonstrates substantial improvement on a clinically significant endpoint over available medicines.

References:

[1] https://www.stocktitan.net/news/RVMD/revolution-medicines-announces-fda-breakthrough-therapy-designation-mkl5b62n30gs.html